Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers.
about
HIV-1 reverse transcriptase mutations that confer decreased in vitro susceptibility to anti-RT DNA aptamer RT1t49 confer cross resistance to other anti-RT aptamers but not to standard RT inhibitors.Generation of Aptamers with an Expanded Chemical RepertoireNucleic acid aptamers: an emerging frontier in cancer therapySmart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapyAptamers in analytics.Use of Aptamers as Diagnostics Tools and Antiviral Agents for Human VirusesAptamer-Drug ConjugatesInhibition of cell proliferation by an anti-EGFR aptamerAptamers and their biological applicationsSelection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cellsRegulating eukaryotic gene expression with aptamers.Peptide ligands selected with CD4-induced epitopes on native dualtropic HIV-1 envelope proteins mimic extracellular coreceptor domains and bind to HIV-1 gp120 independently of coreceptor usageAptamer-targeted cell-specific RNA interferenceNucleic acid aptamers: clinical applications and promising new horizonsAn aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction.Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.HIV-1 subtype C unproductively infects human cardiomyocytes in vitro and induces apoptosis mitigated by an anti-Gp120 aptamer.Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1.Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selectionProtection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics.Cell-specific aptamer-mediated targeted drug deliveryDual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibitionGeneration of neutralizing aptamers against herpes simplex virus type 2: potential components of multivalent microbicides.An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site.UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype CAptamers for Targeted Drug DeliverySelection of 2'-deoxy-2'-fluoroarabinonucleotide (FANA) aptamers that bind HIV-1 reverse transcriptase with picomolar affinityGene therapy progress and prospects: RNA aptamers.Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.RNA as a versatile and powerful platform for engineering genetic regulatory tools.Exploiting herpes simplex virus entry for novel therapeutics.Therapeutic applications of aptamers.Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretroviralsNovel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.Aptamer-based therapeutics: new approaches to combat human viral diseasesNucleic acid based molecular devices.Intracellular delivery of RNA-based therapeutics using aptamers.Characterisation of aptamers for therapeutic studies.Application of aptamers for targeted therapeutics.
P2860
Q24816355-2FBA1420-24A3-4147-9D26-9F31D1B1C1FFQ26782794-BC32F429-02AC-4F06-9527-F65C1ECA63BAQ26849947-E9C43DD2-9BB9-4133-AC12-3250C8034F4CQ27025832-A010B059-E5B1-4286-BD7E-7E2EE73CC38BQ28075607-0E1BB725-8632-4A85-ACCE-2DE7082927CAQ28079654-4F09C43B-DB47-4B2D-A14F-38D83FEE653EQ28468281-9C21C665-4A83-44B5-BE40-7E467D9BE26FQ28743866-52E68A87-EC1D-49E2-B32D-91D49DB2E890Q30470240-B0F040A1-6444-49EE-9A89-74B65EAA3891Q30859838-16A1F1DD-73DF-41FC-B487-743DDD6F2A9AQ31067509-76DCC3BB-492A-4091-9F6B-76253DE1A160Q33640991-12F01139-6070-42C3-986C-F038FF2E1389Q33717239-BD3DB060-CEEE-417B-93B3-968C5D9E3CA0Q34028112-CE4989ED-1961-4B9B-866D-0EA25C6B8EA8Q34092668-CA5318DC-8A31-421A-A850-A6A8A4853321Q34120088-5B80F0CE-8312-43F0-9AC6-EBC846AA33BBQ34232003-774453D5-49A2-4897-90D3-F9195944AB93Q34362343-32AAAB7E-73DA-4CC6-B1F2-94B484FC6971Q34366417-330870F3-D685-4639-9823-AD44F81CBDCCQ34409758-AD2DFEFF-CF05-4B80-BCE4-F2CDC6DC907DQ34509294-5B98AE7B-0ADD-47DA-909A-946B67357CE1Q34599718-9AEDA908-FD53-4937-A666-6BF869363F0AQ35024012-CE27F9D3-2528-4152-8AF7-CF5DB26BB653Q35199134-C38A74C5-37FB-4E40-B7F6-61C4F2324F76Q35234289-DFA5031F-D9F7-45F6-80C8-B9D5731BF2FCQ35943810-5EC00864-9CA4-4806-BFA8-EE604BCCEC4AQ36155891-58DA4168-923F-422F-BA86-A3ACAF2D7D2CQ36575322-D30EB26E-E86A-4174-84B8-15A9D7979E10Q36728599-90BB7DEF-F9DF-47C2-AB29-8EA458A57071Q36839458-50DAD834-B146-4CE3-BD9E-1205B741936CQ37024725-DE41A0D2-3940-4F40-A639-9BD0537174C4Q37030702-5E70EA16-A8DD-443B-A3F6-D60D8F802FC5Q37038988-7E950078-DADB-45BF-9879-57ABB22EBF54Q37247615-617ADF85-B45F-415F-9EA0-D6C32B622048Q37305770-46624574-322B-448D-89D0-DC4A65B13E6DQ37415958-865F440E-63F7-4704-A39D-8BA7AC85BE64Q37857036-E388A82B-0E6D-4E89-AC55-52BFB511BB9EQ37885186-132C18A1-D3C6-443B-8C94-BFEE326DD0C3Q38089865-B5FB0C74-CB9E-43FC-A56E-2CF687CC2C1EQ38096870-FCA2D8B4-A90B-44FA-AD3F-CDAC60958A83
P2860
Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2003
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neutralization of infectivity ...... p120-binding 2'F-RNA aptamers.
@en
Neutralization of infectivity ...... p120-binding 2'F-RNA aptamers.
@nl
type
label
Neutralization of infectivity ...... p120-binding 2'F-RNA aptamers.
@en
Neutralization of infectivity ...... p120-binding 2'F-RNA aptamers.
@nl
prefLabel
Neutralization of infectivity ...... p120-binding 2'F-RNA aptamers.
@en
Neutralization of infectivity ...... p120-binding 2'F-RNA aptamers.
@nl
P2093
P2860
P1433
P1476
Neutralization of infectivity ...... p120-binding 2'F-RNA aptamers.
@en
P2093
Jamal Ibrahim
Makobetsa Khati
Michael Schüman
William James
P2860
P304
12692-12698
P356
10.1128/JVI.77.23.12692-12698.2003
P407
P577
2003-12-01T00:00:00Z